Abstract
Respiratory RNA viruses are constantly evolving, thus requiring development of additional prophylactic and therapeutic strategies. Harnessing the innate immune system to non-specifically respond to viral infection has the advantage of being able to circumvent viral mutations that render the virus resistant to a particular therapeutic agent. Viruses are recognized by various cellular receptors, including Toll-like receptor (TLR) 3 which recognizes doublestranded (ds)RNA produced during the viral replication cycle. TLR3 agonists include synthetic dsRNA such as poly (IC), poly (ICLC) and poly (AU). These agents have been evaluated and found to be effective against a number of viral agents. One major limitation has been the toxicity associated with administration of these drugs. Significant time and effort have been spent to develop alternatives/modifications that will minimize these adverse effects. This review will focus on the TLR3 agonist, poly (IC)/(ICLC) with respect to its use in treatment/prevention of respiratory viral infections.
Keywords: Coronavirus, influenza, innate immune system, respiratory syncytial virus, rhinovirus, poly (ICLC), Toll-like receptor 3
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Volume: 10 Issue: 5
Author(s): M. E. Christopher and J. P. Wong
Affiliation:
Keywords: Coronavirus, influenza, innate immune system, respiratory syncytial virus, rhinovirus, poly (ICLC), Toll-like receptor 3
Abstract: Respiratory RNA viruses are constantly evolving, thus requiring development of additional prophylactic and therapeutic strategies. Harnessing the innate immune system to non-specifically respond to viral infection has the advantage of being able to circumvent viral mutations that render the virus resistant to a particular therapeutic agent. Viruses are recognized by various cellular receptors, including Toll-like receptor (TLR) 3 which recognizes doublestranded (ds)RNA produced during the viral replication cycle. TLR3 agonists include synthetic dsRNA such as poly (IC), poly (ICLC) and poly (AU). These agents have been evaluated and found to be effective against a number of viral agents. One major limitation has been the toxicity associated with administration of these drugs. Significant time and effort have been spent to develop alternatives/modifications that will minimize these adverse effects. This review will focus on the TLR3 agonist, poly (IC)/(ICLC) with respect to its use in treatment/prevention of respiratory viral infections.
Export Options
About this article
Cite this article as:
E. Christopher M. and P. Wong J., Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050327
DOI https://dx.doi.org/10.2174/1871523011109050327 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isolated Tongue Angioedema after Alteplase Infusion in Acute Ischemic
Stroke
Current Drug Safety Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Analgesic Efficacy and Safety of Spinal Oxycodone in Total Hip Arthroplasty: A Preliminary Study
Current Medicinal Chemistry Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Integrative Control of Gastrointestinal Motility by Nitric Oxide
Current Medicinal Chemistry Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Immunosuppression in Liver Transplantation
Current Drug Targets Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Neurotoxicity of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery